Ads
related to: nice guidelines benign prostatic hypertrophycancer.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. [1] Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. [1]
Prostatic artery embolization (PAE, or prostate artery embolisation) is a non-surgical technique for treatment of benign prostatic hyperplasia (BPH). [1]The procedure involves blocking the blood flow of small branches of the prostatic arteries using microparticles injected via a small catheter, [2] to decrease the size of the prostate gland to reduce lower urinary tract symptoms.
A 2019 Cochrane review of 59 studies that included 8924 men with urinary symptoms due to benign prostatic hyperplasia. [4] This review found that bipolar and monopolar TURP probably results in comparable improvements in urinary symptoms, as well as a similar erectile function, the incidence of urinary incontinence, and the need for retreatment.
The International Prostate Symptom Score (IPSS) is an eight-question written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
The American Urological Association (AUA) guidelines for the treatment of BPH from 2018 stated that TUMT may be offered to patients provided they are informed that it is associated with a higher risk of necessary retreatment compared to TURP. [6] The European Association of Urology (EAU) has – as of 2019 – removed TUMT from its guidelines. [7]
Diseases of the bladder and prostate are common health conditions that affect many individuals. Some disorders can cause morbidity and even mortality. [1] Whilst bladder diseases can affect both sexes, prostate diseases are limited to those individuals with male anatomy.